INTRAVENOUS AND ORAL PROPAFENONE IN THE TREATMENT OF PAROXYSMAL ATRIAL-FIBRILLATION

The efficacy of propafenone in the treatment of paroxysmal atrial fibr illation was investigated in 16 patients presenting with frequent and/ or poorly tolerated paroxysmal atrial fibrillation despite prophylacti c treatment in 13 patients. Prolonged atrial fibrillation (>10 minutes ) was triggered in 16 patients following a standard atrial stimulation protocol. Intravenous injection of propafenone (2 mg/kg over 5 minute s) restored sinus rhythm in 12 patients (75 %) within 15 minutes after the end of the injection. In five the 10 patients in whom this was po ssible, propafenone prevented the induction of atrial fibrillation in response to programmed stimulation by the same protocol. Oral propafen one (900 mg/24 hours) was indicated in 11 patients. The treatment was discontinued in 1 patient due to severe dizziness. Atrial fibrillation recurred in 4 patients 10 to 91 days after treatment began. With a me an follow-up time of 8 months, 4 patients had been brought under contr ol and 2 had relapsed despite a generally beneficial effect. Three pat ients suffered side effects which-did not make it necessary to stop tr eatment. This study suggests that intravenous propafenone is effective against persistent atrial fibrillation induced by stimulation. Oral p ropafenone may be useful for the prevention of attacks of recalcitrant paroxysmal atrial fibrillation.